Look at Strides Arcolab: Dipan Mehta

Dipan Mehta, Member at BSE & NSE told CNBC-TV18, "May be Strides Arcolab is pricing in debt at very low interest rates and may be foreign currency buying as well. Having said that what has gone pretty much unnoticed is that Mr Arun Kumar who is the CEO is one of the best deal makers within the pharma industry having had two fantastic exits and now he is buying into this company. So, here is a management who knows little bit or two about how to do the right type of deals within the pharma industry and this would be quite a big leap as far as the company is concerned and going forward with Shasun merger as well as this, a clearer picture is coming as far as the direction of the company and its regaining back its position as one of the dominant players in the generics space as far as the Indian pharmaceutical company is concerned."

"So apart from the valuation one has to look two three years ahead and if all these various acquisitions which the company has done actually starts to deliver and the management has the past track record of getting the best out of these amalgamations we have a good growth story and great returns for investors. Having said that it is a company in which we have investments in and have recommended to our clients. So as a measure of disclosure I would like to state that," he said.